JP2023519602A5 - - Google Patents
Info
- Publication number
- JP2023519602A5 JP2023519602A5 JP2022559368A JP2022559368A JP2023519602A5 JP 2023519602 A5 JP2023519602 A5 JP 2023519602A5 JP 2022559368 A JP2022559368 A JP 2022559368A JP 2022559368 A JP2022559368 A JP 2022559368A JP 2023519602 A5 JP2023519602 A5 JP 2023519602A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- igg4
- igg4 antibody
- constant region
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002631P | 2020-03-31 | 2020-03-31 | |
| US63/002,631 | 2020-03-31 | ||
| PCT/IB2021/052589 WO2021198880A1 (en) | 2020-03-31 | 2021-03-29 | Stabilized igg4 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519602A JP2023519602A (ja) | 2023-05-11 |
| JP2023519602A5 true JP2023519602A5 (enExample) | 2024-04-09 |
Family
ID=77928189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559368A Pending JP2023519602A (ja) | 2020-03-31 | 2021-03-29 | 安定化ＩｇＧ４抗体及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250270325A1 (enExample) |
| EP (1) | EP4126045A4 (enExample) |
| JP (1) | JP2023519602A (enExample) |
| CN (1) | CN115379855A (enExample) |
| WO (1) | WO2021198880A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201014033D0 (en) * | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203071D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| TWI635098B (zh) * | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20190057083A (ko) * | 2016-10-06 | 2019-05-27 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 공정 불순물에 대한 결합이 감소된 항체 |
-
2021
- 2021-03-29 WO PCT/IB2021/052589 patent/WO2021198880A1/en not_active Ceased
- 2021-03-29 US US17/907,683 patent/US20250270325A1/en active Pending
- 2021-03-29 JP JP2022559368A patent/JP2023519602A/ja active Pending
- 2021-03-29 CN CN202180023859.2A patent/CN115379855A/zh active Pending
- 2021-03-29 EP EP21780989.6A patent/EP4126045A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528993A5 (enExample) | ||
| JP6489924B2 (ja) | 定常領域の中に改変を有する抗体変種 | |
| JP2012510282A5 (enExample) | ||
| JP6412083B2 (ja) | 安定なＩｇＧ４抗体 | |
| US11884735B2 (en) | Agonistic anti-IL-2R antibodies and methods of use | |
| AU2010225951B2 (en) | Pharmaceutical formulation containing improved antibody molecules | |
| AU2009290162B2 (en) | Improved antibody molecules | |
| JP5889181B2 (ja) | 抗体定常領域改変体 | |
| JP6622396B2 (ja) | 多重特異性抗体プラットフォームおよびその関連方法 | |
| JP2010527621A5 (enExample) | ||
| JP2022529891A5 (enExample) | ||
| JP2023519602A5 (enExample) | ||
| WO2008081331A2 (en) | Enhancing the level of antibody expression by framework re-engineering | |
| EP4130043A1 (en) | Anti-human cd47 antibody and antigen-binding fragment thereof, and preparation method therefor and use thereof | |
| JP2023519602A (ja) | 安定化ＩｇＧ４抗体及びその使用 | |
| AU2012200724B8 (en) | Improved antibody molecules | |
| WO2024152962A1 (zh) | 抗tt3的人源化抗体及其应用 | |
| WO2025092987A9 (zh) | 基于Fc区的异二聚体分子及其用途 | |
| JP2024511478A5 (enExample) | ||
| HK1163128A (en) | Igg4 antibody variants having modifications in the constant region | |
| HK1163128B (en) | Igg4 antibody variants having modifications in the constant region | |
| HK1190166B (zh) | FCγRIIB特异性FC抗体 |